Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript August 1, 2024Blueprint Medicines Corporation beats earnings expectations.
Blueprint Medicines Corp (BPMC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 2,460,417 | $265,183,744 | -2% | 7.98% |
| 2. | Holocene Advisors Brandon Haley | 943,464 | $101,686,550 | +32% | 0.42% |
| 3. | Alkeon Capital Management Panayotis Takis Sparaggis | 893,928 | $96,347,560 | +13% | 0.15% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 880,147 | $94,862,244 | +7% | 0.9% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 875,000 | $94,307,500 | +2% | 0.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.98 | 1,100 | 92,281 | 2022-11-03 | Filing | ||
| $82.66 | 10 | 5,822 | 2021-07-13 | Filing | ||
| $59.98 | 5,000 | 10,812 | 2022-03-03 | Filing | ||
| $18.00 | 125,000 | Large Shareholder, Other | 2,500,711 | 2015-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $85.12 | 7,734 | 157,557 | 2024-09-09 | Filing | ||
| $85.86 | 11,968 | 165,291 | 2024-09-09 | Filing | ||
| $95.23 | 4,409 | 67,208 | 2024-08-15 | Filing | ||
| $93.19 | 41,913 | 34,729 | 2024-08-05 | Filing | ||
| $111.20 | 3,850 | 43,763 | 2024-07-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,584,176 | $607,324,394 | 0.01% | |
| 2. | 6,114,970 | $564,044,833 | 0.01% | |
| 3. | 4,348,311 | $401,088,207 | 0.03% | |
| 4. | 4,276,333 | $394,448,956 | 0.07% | |
| 5. | 2,424,200 | $223,608,208 | 0.01% |
News See All
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64.
Insiders Are Dumping These 10 Healthcare Stocks
In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
Blueprint Medicines Corporation beats earnings expectations. Reported EPS is $-1.82, expectations were $-2.04.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
Blueprint Medicines Corporation beats earnings expectations. Reported EPS is $-1.82, expectations were $-2.04.
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now.
5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
In this article, we discuss the 5 stocks receiving a massive vote of approval from Wall Street analysts.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Call Transcript
Operator: Good morning. My name is Elliot and I will be your conference operator today.
Billionaire Hedge Funds
